Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
Subscribe To Our Newsletter & Stay Updated
